Mouse models of dengue virus infection and disease

Antiviral Research

Volumn 80, Issue 2, 2008, Pages 87-93

  Yauch, Lauren E ^a   Shresta, Sujan ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Antiviral therapy; Dengue fever; Dengue hemorrhagic fever dengue shock syndrome; Dengue virus; Flavivirus; Mouse model; Vaccine

Indexed keywords

CASTANOSPERMINE 6 BUTYRATE; DENGUE VACCINE; N NONYLDEOXYNOJIRIMYCIN; NOJIRIMYCIN; RIBAVIRIN; UNCLASSIFIED DRUG;

DENGUE; DENGUE VIRUS; DISEASE MODEL; DNA IMMUNIZATION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE DEFICIENCY; INBRED STRAIN; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS RESISTANCE; VIRUS STRAIN;

ANIMALS; CHIMERA; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, INBRED STRAINS; MICE, SCID;

ANIMALIA; DENGUE VIRUS; FLAVIVIRUS; MUS;

EID: 53249130750     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.06.010     Document Type: Review

References (81)

1. An J., Kimura-Kuroda J., Hirabayashi Y., and Yasui K. Development of a novel mouse model for dengue virus infection. Virology 263 (1999) 70-77
2. Beaumier C.M., Mathew A., Bashyam H.S., and Rothman A.L. Cross-reactive memory CD8(+) T cells alter the immune response to heterologous secondary dengue virus infections in mice in a sequence-specific manner. J. Infect. Dis. 197 (2008) 608-617
3. Bente D.A., Melkus M.W., Garcia J.V., and Rico-Hesse R. Dengue fever in humanized NOD/SCID mice. J. Virol. 79 (2005) 13797-13799
4. Blaney Jr. J.E., Matro J.M., Murphy B.R., and Whitehead S.S. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J. Virol. 79 (2005) 5516-5528
5. Blaney Jr. J.E., Johnson D.H., Manipon G.G., Firestone C.Y., Hanson C.T., Murphy B.R., and Whitehead S.S. Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology 300 (2002) 125-139
6. Bray M., Zhao B.T., Markoff L., Eckels K.H., Chanock R.M., and Lai C.J. Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus encephalitis. J. Virol. 63 (1989) 2853-2856
7. Burke D.S., Nisalak A., Johnson D.E., and Scott R.M. A prospective study of dengue infections in Bangkok. Am. J. Trop. Med. Hyg. 38 (1988) 172-180
8. Calvert A.E., Huang C.Y., Kinney R.M., and Roehrig J.T. Non-structural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge. J. Gen. Virol. 87 (2006) 339-346
9. Chambers T.J., Hahn C.S., Galler R., and Rice C.M. Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 44 (1990) 649-688
10. Chen H.C., Hofman F.M., Kung J.T., Lin Y.D., and Wu-Hsieh B.A. Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virus-induced hemorrhage. J. Virol. 81 (2007) 5518-5526
11. Chen H.C., Lai S.Y., Sung J.M., Lee S.H., Lin Y.C., Wang W.K., Chen Y.C., Kao C.L., King C.C., and Wu-Hsieh B.A. Lymphocyte activation and hepatic cellular infiltration in immunocompetent mice infected by dengue virus. J. Med. Virol. 73 (2004) 419-431
12. Chen L., Ewing D., Subramanian H., Block K., Rayner J., Alterson K.D., Sedegah M., Hayes C., Porter K., and Raviprakash K. A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques. J. Virol. 81 (2007) 11634-11639
13. Chen S.T., Lin Y.L., Huang M.T., Wu M.F., Cheng S.C., Lei H.Y., Lee C.K., Chiou T.W., Wong C.H., and Hsieh S.L. CLEC5A is critical for dengue-virus-induced lethal disease. Nature 453 (2008) 672-676
14. Chen Y., Maguire T., Hileman R.E., Fromm J.R., Esko J.D., Linhardt R.J., and Marks R.M. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3 (1997) 866-871
15. Cole G.A., and Wisseman Jr. C.L. Pathogenesis of type 1 dengue virus infection in suckling, weanling and adult mice. 1. The relation of virus replication to interferon and antibody formation. Am. J. Epidemiol. 89 (1969) 669-680
16. Courageot M.P., Frenkiel M.P., Dos Santos C.D., Deubel V., and Despres P. Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J. Virol. 74 (2000) 564-572
17. Diamond M.S., Zachariah M., and Harris E. Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. Virology 304 (2002) 211-221
18. Diamond M.S., Roberts T.G., Edgil D., Lu B., Ernst J., and Harris E. Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons. J. Virol. 74 (2000) 4957-4966
19. Durbin J.E., Hackenmiller R., Simon M.C., and Levy D.E. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84 (1996) 443-450
20. Falgout B., Bray M., Schlesinger J.J., and Lai C.J. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J. Virol. 64 (1990) 4356-4363
21. Fu J., Tan B.H., Yap E.H., Chan Y.C., and Tan Y.H. Full-length cDNA sequence of dengue type 1 virus (Singapore strain S275/90). Virology 188 (1992) 953-958
22. Goncalvez A.P., Engle R.E., St Claire M., Purcell R.H., and Lai C.J. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 9422-9427
23. Green S., Vaughn D.W., Kalayanarooj S., Nimmannitya S., Suntayakorn S., Nisalak A., Lew R., Innis B.L., Kurane I., Rothman A.L., and Ennis F.A. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J. Infect. Dis. 179 (1999) 755-762
24. Gubler D.J. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11 (1998) 480-496
25. Guirakhoo F., Pugachev K., Arroyo J., Miller C., Zhang Z.X., Weltzin R., Georgakopoulos K., Catalan J., Ocran S., Draper K., and Monath T.P. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298 (2002) 146-159
26. Halstead S.B. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J. Infect. Dis. 140 (1979) 527-533
27. Halstead S.B. Pathogenesis of dengue: challenges to molecular biology. Science 239 (1988) 476-481
28. Halstead S.B., Shotwell H., and Casals J. Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J. Infect. Dis. 128 (1973) 15-22
29. Halstead S.B., Shotwell H., and Casals J. Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection. J. Infect. Dis. 128 (1973) 7-14
30. Hotta H., Murakami I., Miyasaki K., Takeda Y., Shirane H., and Hotta S. Inoculation of dengue virus into nude mice. J. Gen. Virol. 52 (1981) 71-76
31. Hotta S. Experimental studies on dengue. I. Isolation, identification and modification of the virus. J. Infect. Dis. 90 (1952) 1-9
32. Huang K.J., Li S.Y., Chen S.C., Liu H.S., Lin Y.S., Yeh T.M., Liu C.C., and Lei H.Y. Manifestation of thrombocytopenia in dengue-2-virus-infected mice. J. Gen. Virol. 81 (2000) 2177-2182
33. Imrie A., Meeks J., Gurary A., Sukhbataar M., Kitsutani P., Effler P., and Zhao Z. Differential functional avidity of dengue virus-specific T-cell clones for variant peptides representing heterologous and previously encountered serotypes. J. Virol. 81 (2007) 10081-10091
34. Jessie K., Fong M.Y., Devi S., Lam S.K., and Wong K.T. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J. Infect. Dis. 189 (2004) 1411-1418
35. Johnson A.J., and Roehrig J.T. New mouse model for dengue virus vaccine testing. J. Virol. 73 (1999) 783-786
36. Kaufman B.M., Summers P.L., Dubois D.R., and Eckels K.H. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 36 (1987) 427-434
37. Kliks S.C., Nisalak A., Brandt W.E., Wahl L., and Burke D.S. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40 (1989) 444-451
38. Kuruvilla J.G., Troyer R.M., Devi S., and Akkina R. Dengue virus infection and immune response in humanized RAG2(-/-)gamma(c)(-/-) (RAG-hu) mice. Virology 369 (2007) 143-152
39. Kyle J.L., Beatty P.R., and Harris E. Dengue virus infects macrophages and dendritic cells in a mouse model of infection. J. Infect. Dis. 195 (2007) 1808-1817
40. Lee E., Wright P.J., Davidson A., and Lobigs M. Virulence attenuation of dengue virus due to augmented glycosaminoglycan-binding affinity and restriction in extraneural dissemination. J. Gen. Virol. 87 (2006) 2791-2801
41. Lin Y.L., Liao C.L., Chen L.K., Yeh C.T., Liu C.I., Ma S.H., Huang Y.Y., Huang Y.L., Kao C.L., and King C.C. Study of dengue virus infection in SCID mice engrafted with human K562 cells. J. Virol. 72 (1998) 9729-9737
42. Lozach P.Y., Burleigh L., Staropoli I., Navarro-Sanchez E., Harriague J., Virelizier J.L., Rey F.A., Despres P., Arenzana-Seisdedos F., and Amara A. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals. J. Biol. Chem. 280 (2005) 23698-23708
43. Lum L.C., Lam S.K., Choy Y.S., George R., and Harun F. Dengue encephalitis: a true entity?. Am. J. Trop. Med. Hyg. 54 (1996) 256-259
44. Mangada M.M., and Rothman A.L. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J. Immunol. 175 (2005) 2676-2683
45. Mangada M.M., Endy T.P., Nisalak A., Chunsuttiwat S., Vaughn D.W., Libraty D.H., Green S., Ennis F.A., and Rothman A.L. Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren. J. Infect. Dis. 185 (2002) 1697-1703
46. Marchette N.J., Halstead S.B., Falkler Jr. W.A., Stenhouse A., and Nash D. Studies on the pathogenesis of dengue infection in monkeys. 3. Sequential distribution of virus in primary and heterologous infections. J. Infect. Dis. 128 (1973) 23-30
47. McBride W.J., and Bielefeldt-Ohmann H. Dengue viral infections; pathogenesis and epidemiology. Microbes Infect. 2 (2000) 1041-1050
48. Miller J.L., deWet B.J., Martinez-Pomares L., Radcliffe C.M., Dwek R.A., Rudd P.M., and Gordon S. The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog. 4 (2008) e17
49. Mongkolsapaya J., Dejnirattisai W., Xu X.N., Vasanawathana S., Tangthawornchaikul N., Chairunsri A., Sawasdivorn S., Duangchinda T., Dong T., Rowland-Jones S., Yenchitsomanus P.T., McMichael A., Malasit P., and Screaton G. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9 (2003) 921-927
50. Mongkolsapaya J., Duangchinda T., Dejnirattisai W., Vasanawathana S., Avirutnan P., Jairungsri A., Khemnu N., Tangthawornchaikul N., Chotiyarnwong P., Sae-Jang K., Koch M., Jones Y., McMichael A., Xu X., Malasit P., and Screaton G. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal?. J. Immunol. 176 (2006) 3821-3829
51. Morens D.M., and Halstead S.B. Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies. J. Gen. Virol. 71 (1990) 2909-2914
52. Morens D.M., Halstead S.B., and Marchette N.J. Profiles of antibody-dependent enhancement of dengue virus type 2 infection. Microb. Pathog. 3 (1987) 231-237
53. Olsen D.B., Eldrup A.B., Bartholomew L., Bhat B., Bosserman M.R., Ceccacci A., Colwell L.F., Fay J.F., Flores O.A., Getty K.L., Grobler J.A., LaFemina R.L., Markel E.J., Migliaccio G., Prhavc M., Stahlhut M.W., Tomassini J.E., MacCoss M., Hazuda D.J., and Carroll S.S. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob. Agents Chemother. 48 (2004) 3944-3953
54. Paes M.V., Pinhao A.T., Barreto D.F., Costa S.M., Oliveira M.P., Nogueira A.C., Takiya C.M., Farias-Filho J.C., Schatzmayr H.G., Alves A.M., and Barth O.M. Liver injury and viremia in mice infected with dengue-2 virus. Virology 338 (2005) 236-246
55. Patey O., Ollivaud L., Breuil J., and Lafaix C. Unusual neurologic manifestations occurring during dengue fever infection. Am. J. Trop. Med. Hyg. 48 (1993) 793-802
56. Rothman A.L., Kurane I., and Ennis F.A. Multiple specificities in the murine CD4+ and CD8+ T-cell response to dengue virus. J. Virol. 70 (1996) 6540-6546
57. Sabin A.B. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1 (1952) 30-50
58. Sabin A.B., and Schlesinger R.W. Production of immunity to dengue with virus modified by propagation in mice. Science 101 (1945) 640-642
59. Sangkawibha N., Rojanasuphot S., Ahandrik S., Viriyapongse S., Jatanasen S., Salitul V., Phanthumachinda B., and Halstead S.B. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong Thailand. I. The 1980 outbreak. Am. J. Epidemiol. 120 (1984) 653-669
60. Scherer W.F., Russell P.K., Rosen L., Casals J., and Dickerman R.W. Experimental infection of chimpanzees with dengue viruses. Am. J. Trop. Med. Hyg. 27 (1978) 590-599
61. Schneider B.S., and Higgs S. The enhancement of arbovirus transmission and disease by mosquito saliva is associated with modulation of the host immune response. Trans. R. Soc. Trop. Med. Hyg. 102 (2008) 400-408
62. Schul W., Liu W., Xu H.Y., Flamand M., and Vasudevan S.G. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J. Infect. Dis. 195 (2007) 665-674
63. Seneviratne S.L., Malavige G.N., and de Silva H.J. Pathogenesis of liver involvement during dengue viral infections. Trans. R. Soc. Trop. Med. Hyg. 100 (2006) 608-614
64. Shresta S., Kyle J.L., Beatty P.R., and Harris E. Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice. Virology 319 (2004) 262-273
65. Shresta S., Sharar K.L., Prigozhin D.M., Beatty P.R., and Harris E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 80 (2006) 10208-10217
66. Shresta S., Kyle J.L., Snider H.M., Basavapatna M., Beatty P.R., and Harris E. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J. Virol. 78 (2004) 2701-2710
67. Spillmann D. Heparan sulfate: anchor for viral intruders?. Biochimie 83 (2001) 811-817
68. Stein D.A., and Shi P.Y. Nucleic acid-based inhibition of flavivirus infections. Front. Biosci. 13 (2008) 1385-1395
69. Styer L.M., Kent K.A., Albright R.G., Bennett C.J., Kramer L.D., and Bernard K.A. Mosquitoes inoculate high doses of West Nile virus as they probe and feed on live hosts. PLoS Pathog. 3 (2007) 1262-1270
70. Sun W., Nisalak A., Gettayacamin M., Eckels K.H., Putnak J.R., Vaughn D.W., Innis B.L., Thomas S.J., and Endy T.P. Protection of rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. J. Infect. Dis. 193 (2006) 1658-1665
71. Takhampunya R., Ubol S., Houng H.S., Cameron C.E., and Padmanabhan R. Inhibition of dengue virus replication by mycophenolic acid and ribavirin. J. Gen. Virol. 87 (2006) 1947-1952
72. Tassaneetrithep B., Burgess T.H., Granelli-Piperno A., Trumpfheller C., Finke J., Sun W., Eller M.A., Pattanapanyasat K., Sarasombath S., Birx D.L., Steinman R.M., Schlesinger S., and Marovich M.A. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J. Exp. Med. 197 (2003) 823-829
73. van Der Most R.G., Murali-Krishna K., Ahmed R., and Strauss J.H. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J. Virol. 74 (2000) 8094-8101
74. Wang E., Ni H., Xu R., Barrett A.D., Watowich S.J., Gubler D.J., and Weaver S.C. Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. J. Virol. 74 (2000) 3227-3234
75. Whitby K., Pierson T.C., Geiss B., Lane K., Engle M., Zhou Y., Doms R.W., and Diamond M.S. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J. Virol. 79 (2005) 8698-8706
76. Whitehead S.S., Blaney J.E., Durbin A.P., and Murphy B.R. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 5 (2007) 518-528
77. Whitehead S.S., Falgout B., Hanley K.A., Blaney Jr. J.E., Markoff L., and Murphy B.R. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys. J. Virol. 77 (2003) 1653-1657
78. WHO. Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention and Control. 2nd ed. (1997), WHO, Geneva
79. Wu S.F., Lee C.J., Liao C.L., Dwek R.A., Zitzmann N., and Lin Y.L. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 76 (2002) 3596-3604
80. Wu S.J., Hayes C.G., Dubois D.R., Windheuser M.G., Kang Y.H., Watts D.M., and Sieckmann D.G. Evaluation of the severe combined immunodeficient (SCID) mouse as an animal model for dengue viral infection. Am. J. Trop. Med. Hyg. 52 (1995) 468-476
81. Wu S.J., Grouard-Vogel G., Sun W., Mascola J.R., Brachtel E., Putvatana R., Louder M.K., Filgueira L., Marovich M.A., Wong H.K., Blauvelt A., Murphy G.S., Robb M.L., Innes B.L., Birx D.L., Hayes C.G., and Frankel S.S. Human skin Langerhans cells are targets of dengue virus infection. Nat. Med. 6 (2000) 816-820